Parkinson's disease

Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But while a tremor may be the most well-known sign of Parkinson's disease, the disorder also commonly causes stiffness or slowing of movement.

In the early stages of Parkinson's disease, your face may show little or no expression, or your arms may not swing when you walk. Your speech may become soft or slurred. Parkinson's disease symptoms worsen as your condition progresses over time.

Treatments today for PD include medications that can provide relief from the many symptoms associated with the condition. Some medications work by assisting in the performance of neurotransmitters in the brain responsible for the transfer information from one cell to another. In some cases, regulations of certain regions of the brain are necessary for improvement of symptoms. Many herbal remedies and supplements are also available for use to help relieve symptoms experienced in patients with PD.

 

Which Kinds of cells are used in Parkinson’s disease and how are they obtained?

Adult stem cells are obtained from ITC bank from donor tissue or autologous transplant, which is harvested from the patient’s own adipose tissue and it takes 21 days to culture, differentiate and administer the adult stem cells to the patient.

 

How are Mesenchymal Stem Cells (MSC) administered in Parkinsons Disease?

A typical treatment is as following: stem cells  are administered by a license physician.

Medical evaluation, blood testing, Hyperbaric Chamber (Day 1)
intrathecal injections of adipose derive Mesenchymal Stem Cells (Day 2)

1 intravenous injections of adipose tissue-derived mesenchymal stem cells , with Vit. C, Eicosanoids and Aminoacids (day 3)

 

Mochizuki, H., Choong, C., & Yasuda, T. (2014). The promises of stem cells: stem cell therapy for movement disorders. Parkinsonism & Related Disorders, 20, S128-S131. http://dx.doi.org/10.1016/s1353-8020(13)70031-2

Moriyama, M., Moriyama, H., Ueda, A., Nishibata, Y., Okura, H., & Ichinose, A. et al. (2012). Human adipose tissue-derived multilineage progenitor cells exposed to oxidative stress induce neurite outgrowth in PC12 cells through p38 MAPK signaling. BMC Cell Biol, 13(1), 21. http://dx.doi.org/10.1186/1471-2121-13-21

Inden, M., Takata, K., Nishimura, K., Kitamura, Y., Ashihara, E., & Yoshimoto, K. et al. (2012). Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice. J. Neurosci. Res., n/a-n/a. http://dx.doi.org/10.1002/jnr.23128